SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Paratek Pharmaceuticals, Inc. (PRTK)

Add PRTK Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 9/4/2016 2:24:02 PM - Followers: 0 - Board type: Free - Posts Today: 0
Paratek Pharmaceuticals, Inc.

75 Park Plaza
Boston, MA 02116
United States

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include Omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
PRTK News: Paratek Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results and Provides Clinical Updates 11/02/2016 07:30:00 AM
PRTK News: Quarterly Report (10-q) 11/02/2016 06:08:50 AM
PRTK News: Paratek Pharmaceuticals, Inc. to Host R&D Day on November 17, 2016 10/26/2016 08:00:00 AM
PRTK News: Paratek Pharmaceuticals to Report Third Quarter 2016 Financial Results and Provide Update on Clinical Progress on November 2,... 10/24/2016 08:00:00 AM
PRTK News: Paratek, U.S. Department of Defense Enter Research Agreement to Study Omadacycline Against Biodefense Pathogens 10/11/2016 08:00:00 AM
#2   PRTK bullish 13.61 stocktrademan 09/04/16 02:24:02 PM
#1   PRTK bearish 13.38 stocktrademan 07/16/16 12:39:44 PM